Selected References:
- DeSisto CL, et al. 2021. Risk of stillbirth among women with and without COVID-19 at delivery hospitalization – United States, March 2020 – September 2021. MMWR Morb Mortal Wkly Rep 70:1640–1645.
- Kasehagen L, et al. 2021. COVID-19 – associated deaths after SARS-CoV-2 infection during pregnancy – Mississippi, March 1, 2020 – October 6, 2021. MMWR Morb Mortal Wkly Rep 70:1646–1648.
- Merck & Co., Inc. 2021. Center for Drug Evaluation and Research Antimicrobial Drugs Advisory Committee Meeting Briefing Document. Molnupiravir. Available at https://www.fda.gov/media/154421/download
- Regan AK, et al. 2022. SARS-CoV-2 infection during pregnancy and associated perinatal health outcomes: a national US cohort study. J Infect Dis 225(5):759-767.
- S. Food & Drug Administration, Antimicrobial Drugs Advisory Committee. November 30, 2021. Molnupiravir. Available at https://www.fda.gov/media/154472/download
- U.S. Food & Drug Administration. 2021 (Revised October 2023). Fact Sheet for Healthcare Providers: Emergency Use Authorization for Molnupiravir. Available at https://www.fda.gov/media/155054/download
